The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Pacritinib moves foward in MF: PAC2013 and PACIFICA
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the use of pacritinib, an oral JAK2/IRAK1 inhibitor, compared with other therapies in myelofibrosis (MF), which has an upcoming phase 3 trial – PACIFICA. He also highlights the PAC2013 dose-finding study of pacritinib in patients with MF (NCT03165734). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
